RCKT
Rocket Pharmaceuticals, Inc.Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-06-12 |
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
CRANBURY, N.J. --(BUSINESS WIRE)--Jun. 12, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the closing of the sale of its |
| 2026-05-28 |
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
CRANBURY, N.J. --(BUSINESS WIRE)--May 28, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate |
| 2026-05-07 |
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Pivotal Phase 2 trial of RP-A501 for Danon disease progressing with dosing reinitiated First patient dosing in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026 KRESLADI™ granted FDA accelerated approval; Rare Pediatric Disease Priority Review Voucher |
| 2026-04-28 |
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
PRV monetization provides $180 million in non-dilutive capital to support cardiovascular pipeline Cash runway extended into the second quarter of 2028 CRANBURY, N.J. --(BUSINESS WIRE)--Apr. 28, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology |
| 2026-03-27 |
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2 Severe LAD-I is an ultra-rare, life-threatening pediatric genetic immunodeficiency characterized by recurrent infections and high early-childhood mortality without treatment FDA grants Rare Pediatric |
| 2026-02-26 |
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026 KRESLADI ™ for severe LAD-I on track for March 28, 2026 PDUFA date Dosing of first patient in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026 Cash, cash equivalents and investments of |
| 2026-02-23 |
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
CRANBURY, N.J. --(BUSINESS WIRE)--Feb. 23, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the |
| 2026-01-05 |
Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
CRANBURY, N.J. --(BUSINESS WIRE)--Jan. 5, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the |
| 2025-11-25 |
Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
CRANBURY, N.J. --(BUSINESS WIRE)--Nov. 25, 2025-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the |
| 2025-11-06 |
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026 KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date Leadership updates with the appointments of Dr. Syed Rizvi , Chief Medical Officer, Christopher Stevens , Chief Operating Officer, and Sarbani Chaudhuri , Chief |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-06-09 | Goldman Sachs 47th Annual Global Healthcare Conference | Conference |
| 2026-06-04 | Jefferies Global Healthcare Conference | Conference |
| 2026-03-27 | KRESLADI™ FDA Approval Investor Conference Call | Conference |
| 2026-03-10 | Leerink Partners Global Healthcare Conference | Conference |
| 2026-03-02 | TD Cowen 46th Annual Health Care Conference | Conference |
| 2026-01-14 | 44th Annual J.P. Morgan Healthcare Conference | Conference |
| 2026-01-14 | 44th Annual J.P. Morgan Healthcare Conference | Conference |
| 2025-12-02 | 8th Annual Evercore Healthcare Conference | Conference |
| 2025-09-09 | Morgan Stanley 23rd Annual Global Healthcare Conference | Conference |
| 2025-09-03 | 2025 Cantor Fitzgerald Global Healthcare Conference | Conference |
| 2025-05-27 | Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease | Event |
Source: https://ir.rocketpharma.com/